Chronic Myeloid Leukemia


Sprycel May Be More Effective than Gleevec for Initial Treatment of CML (June 5, 2010)

In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 29, 2010)

For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar... Continue Reading

Tasigna May Be More Effective than Gleevec for Initial Treatment of CML (January 28, 2010)

In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading

Accelerated Phase Overview (July 30, 2009)

Overview Chronic myeloid leukemia (CML) is the abnormal growth of relatively mature myeloid white blood cells. The disease is associated with a chromosomal abnormality in which genetic material from chromosome... Continue Reading

Sprycel® Superior to High-dose Gleevec® in Gleevec-resistant CML (July 1, 2009)

Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according... Continue Reading

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)

Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma,... Continue Reading

Cancer’s Glamour Girl (March 20, 2009)

Down-to-earth and down-to-business when it comes to cancer advocacy, Erin Zammett Ruddy discusses her very public journey with chronic myeloid leukemia and why she continues to share her story. by Diana... Continue Reading

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (January 30, 2009)

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois,... Continue Reading

Early Dose Intensity of Gleevec® May Optimize Response for Chronic Phase CML (January 20, 2009)

Early Dose Intensity of Gleevec® May Optimize Response for Chronic Phase CML Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) who receive high doses (600 mg) of Gleevec®... Continue Reading

LYN Kinase Affects Sensitivity to Gleevec® in Chronic Myeloid Leukemia (July 1, 2008)

LYN Kinase Affects Sensitivity to Gleevec® in Chronic Myeloid Leukemia A protein structure known as the LYN kinase appears to play an important role in the effectiveness of Gleevec® (imatinib mesylate)... Continue Reading

Sprycel® Effective for Newly Diagnosed Chronic Myeloid Leukemia (June 27, 2008)

Sprycel® Effective for Newly Diagnosed Chronic Myeloid Leukemia The targeted agent Sprycel® (dasatinib) is an effective treatment for patients newly diagnosed with chronic myeloid leukemia (CML). These... Continue Reading

Tasigna® Effective for Patients with Newly Diagnosed Chronic Myeloid Leukemia (June 25, 2008)

Tasigna® Effective for Patients with Newly Diagnosed Chronic Myeloid Leukemia The targeted agent Tasigna® (nilotinib) appears to be an effective treatment for patients with newly diagnosed chronic... Continue Reading

Advances in the Management of Chronic Myeloid Leukemia (January 21, 2008)

Advances in the Management of Chronic Myeloid Leukemia: A Report from the 2007 American Society of Hematology (ASH) Meeting IntroductionInitial Treatment of Newly Diagnosed PatientsAre Higher Doses of... Continue Reading

Supportive Care and Hematologic Malignancies (January 21, 2008)

Supportive Care and Hematologic Malignancies: A Report from the 2007 American Society of Hematology (ASH) Meeting Introduction At the 2007 meeting of the American Society of Hematology (ASH) the most interesting... Continue Reading

Tasigna® Approved for Chronic Myeloid Leukemia (November 1, 2007)

Tasigna® Approved for Chronic Myeloid Leukemia (CML) The United States Food and Drug Administration (FDA) has approved the targeted agent Tasigna® (nilotinib) for the treatment of chronic and accelerated-phase... Continue Reading

Updates in the Management of Chronic Myeloid Leukemia (CML): A Report from ASCO 2007 (October 12, 2007)

Updates in the Management of Chronic Myeloid Leukemia (CML): A Report from ASCO 2007 Introduction Imatinib (Gleevec®) is the standard initial treatment of newly diagnosed chronic myeloid leukemia (CML).... Continue Reading

« Previous PageNext Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS